NCT05279352 - Safety and Pharmacokinetics of FBR-002 for the Treatment of Patients Hospitalized With COVID-19 in Need of Supplemental Oxygen and at Risk of Severe Outcome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

June 15, 2022

Study Completion Date

July 15, 2022

Conditions

COVID-19

Interventions

DRUG

FBR-002

Administration on D1 and D3

DRUG

Placebo

Administration on D1 and D3

Trial Locations (6)

RECRUITING

University General Hospital of Athens ATTIKON, Athens

RECRUITING

University General Hospital of Patras, Pátrai

RECRUITING

University General Hospital of Alexandroupolis, Alexandroupoli

RECRUITING

"Sotiria General Hospital of Chest Diseases of Athens", Athens

RECRUITING

"Tzaneio General Hospital of Piraeus", Piraeus

RECRUITING

AHEPA University General Hospital of Thessaloniki, Thessaloniki